Servier Pipeline

February 2026

SERVIER
moved by you

FOCUSED ON EXPANDING OUR PIPELINE



Data as of February 2026
** Single Pill Combination & New Formulation*

Oncology – Solid Tumors

As data of February 2026

	Target	Indication	PCD**	Phase I/II	Phase II	Phase III Potential registration	Partenaire
DAROVASERTIB	PKC	**Uveal melanoma**					IDEAYA BIOSCIENCES
IVOSIDENIB	IDH1	**Chondrosarcoma**					
IVOSIDENIB / + durvalumab +gemcitabine/cisplatine	IDH1	**Cholangiocarcinoma**					
VORASIDENIB / + temozolomide	IDH1/2	**Glioma**					
VORASIDENIB / + pembrolizumab	IDH1/2	**Glioma**					
S095018	TIM3	**Non-small Cell Lung Cancer (in association)**					
S095024	CD73	**Non-small Cell Lung Cancer (in association)**					
S095029	NKG2A	**Non-small Cell Lung Cancer (in association)**					
		Gastric cancer					
S095035	MAT2A	**Solid tumors**					
S241656	RAS, RAF	**Solid tumors**					

** Not Disclose*
***Preclinical development phase*

Oncology – Hematological malignancies

As data of February 2026

	Cible	Indication	PCD**	Phase I/II	Phase II	Phase III Potential registration	Partenaire
IVOSIDENIB / + 7+3 (chemotherapy)	IDH1	**Acute Myeloid Leukemia** (new indication)					
IVOSIDENIB / azacitidine / venetoclax							
IVOSIDENIB							
CEMACABTAGENE ANSEGEDLEUCEL (Cema-Cel)[1]	CD19	**Diffuse Large B-Cell Lymphoma**					Licensed from Cellectis and Sub-Licensed to Allogene*
S243249	MENIN	• **Acute Myeloid Leukemia** • **Acute Lymphoblastic Leukemia**					Vernalis
S236220	*ND**	**Hematological malignancies**					
S247567	*ND**						

[1]Cema-Cel (ALLO501.A /S 95023) utilize TALEN® gene-editing technology owned by Cellectis. Servier, which has an exclusive license to the anti-CD19 investigational products from Cellectis, has granted Allogene exclusive rights to develop and commercialize Cema-Cel in the U.S., all EU Member States and the United Kingdom. For other candidate products (UCART19v1 and ALLO 501) sub-licensed to Allogene, the ongoing activities are limited to follow up of patients from discontinued trials as per regulatory obligations.

** Not Disclose*
***Preclinical development phase*

SERVIER

Neurology

As data of February 2026

	Target	Indication	PCD**	Phase I/II	Phase II	Phase III Potential registration
Genetically driven autism spectrum disorder Chemical entity	BK channel	**Fragile X syndrome** is a genetic disorder caused by a mutation in the FMR1 gene, leading to a deficiency of the fragile X mental retardation protein (FMRP). This protein is crucial for normal brain development and function. The absence of FMRP disrupts synaptic plasticity, which is essential for learning and memory, resulting in cognitive impairments and behavioral challenges. Patients with Fragile X syndrome often exhibit a range of symptoms, including intellectual disability, anxiety, and social difficulties. The condition can also manifest itself through physical features such as an elongated face and enlarged ears.				

***Preclinical development phase*

Neurology

As data of February 2026

	Target	Indication	PCD**	Phase I/II	Phase II	Phase III Potential registration
Developmental and epileptic encephalopathies AntiSense Oligonucleotide	KCNT1	KCNT1-related **Developmental and Epileptic Encephalopathy** (DEE) are a group of severe neurological disorders characterized by very early-onset seizures and significant developmental delays. KCNT1-DEE is caused by genetic mutations in the KCNT1 gene that disrupt normal brain development and function. The seizures are most often refractory to standard anti-epileptic medication, complicating treatment. Patients with KCNT1-DEE experience a range of symptoms, including severe cognitive impairments, motor deficits, and behavioral issues. The impact on family dynamics and overall quality of life is profound. More details about ASO technology				

**Preclinical development phase*

Neurology

As data of February 2026

	Target	Indication	PCD**	Phase I/II	Phase II	Phase III Potential registration
Movement disorder	ND*	**Movement disorders** are a diverse group of neurological conditions characterized by abnormal movements that significantly impact daily functioning. These disorders are often due to genetic mutations, neurodegenerative processes, or environmental factors affecting the brain's motor control pathways. Common examples include sustained muscle contractions and abnormal postures, as irregular, rapid movements difficult to control. Patients with rare movement disorders often face challenges in mobility, communication, and social interactions. The unpredictability of symptoms is often associated with emotional distress and a reduced quality of life.				

**Not DIsclosed*
***Preclinical development phase*

Cardio-metabolic & Venous Diseases

As data of February 2026

	Indication	PCD**	Phase I/II	Phase II	Phase III Potential registration	Filing
Ivabradine (new formulation)	**Heart Failure**					
Dapagliflozin/Bisoprolol	**Heart Failure**					
Bisoprolol/Perindopril/Indapamide/Amlodipine	**Hypertension**					
Perindopril/Indapamide SR/Amlodipine	**Hypertension**					
Gliclazide/Metformin	**T2 diabetes**					
Bisoprolol/Perindopril/Amlodipine	**Hypertension**					
Dapagliflozin/Gliclazide (2 formulations)	**T2 diabetes**					

+4 ON GOING FEASIBILITY PROJECTS

***Preclinical development phase*